NCI Denies Media Report It Failed to Replicate Endostatin Findings

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 11
Volume 8
Issue 11

BETHESDA, Md-In a rare public confrontation with the media, the National Cancer Institute denied a report in the Wall Street Journal that its scientists had failed to replicate the work of Judah Folkman, PhD, showing that endostatin, an antiangiogenesis compound, dramatically shrinks tumors in mice.

BETHESDA, Md—In a rare public confrontation with the media, the National Cancer Institute denied a report in the Wall Street Journal that its scientists had failed to replicate the work of Judah Folkman, PhD, showing that endostatin, an antiangiogenesis compound, dramatically shrinks tumors in mice.

The NCI said that in February, two of its scientists conducted experiments in Dr. Folkman’s laboratory at Children’s Hospital, Boston that verified his previously published results. As a result of that work, the NCI said it decided to proceed with two phase I endostatin trials, one of which is now enrolling patients.

The Institute statement said that it had not conducted additional experiments with human or murine endostatin at any of its laboratories in Maryland, “meaning there have been no ‘failed’ laboratory studies with the material to be used in humans.” It noted that other experimenters had found that, in mice, human endostatin had caused “a marked inhibition of tumor growth, an indication that the human protein might also be effective in people".

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
2 experts are featured in this series.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Related Content